BS

Bandel Sharmila

Active Director Additional Director DIN 09769705
DIN 09769705 First appointment Oct 2022 Primary industry Research & Development
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Oct 2022
Shareholding value β€’β€’β€’β€’ Premium profile

About Bandel Sharmila

Data last updated:

Bandel Sharmila is an Additional Director at Mentriix Clinical Research Private Limited (since 2022). The company operates in Research & Development.

DIN 09769705
Primary Designation Additional Director
Industry Research & Development
First Appointment 08 Oct 2022
Oldest Company Age 6 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Additional Director08 Oct 20222020Active

Board colleagues of Bandel Sharmila

NameDINCompanyDesignation
Swathi Gadala08659263Mentriix Clinical Research Private LimitedDirector

Directorship timeline

Open interactive timeline →
Mentriix Clinical Research Private Limited
Premium access

Shareholding and investment profile for Bandel Sharmila

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Bandel Sharmila

Bandel Sharmila currently holds 1 directorship: Mentriix Clinical Research Private Limited (Additional Director, since 08 Oct 2022).

Bandel Sharmila was first appointed on 08 Oct 2022 as Additional Director at Mentriix Clinical Research Private Limited.

The current boards of Bandel Sharmila's companies include Swathi Gadala (Mentriix Clinical Research Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available